Skip to content

Study · Case report or series · n = 1 · 2023

9 results

Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.

Zaitoon H, Lubetzky R, Amir AZ, Moran-Lev H, Sagi L, Yacobi-Bach M, Borger O, Chorna E, Lebenthal Y, Brener A

Acta diabetologica9 May 2023Cited by 8 (Europe PMC)

PMID37160786 (opens in a new tab)DOI10.1007/s00592-023-02109-9 (opens in a new tab)PepBankPUB-37160786
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a boy with severe obesity due to a homozygous MC4R mutation, one year of liraglutide halted progressive weight gain (BMI 50.3 kg/m2).

    In plain wordsIn one boy with a gene-related severe obesity, a year of liraglutide stopped his weight gain.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI, case 1 (MC4R mutation)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    BMI
    50.3 kg/m2
    after 1 year

    Source sentences

    Summary
    One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement.
    1 context sentence
    Summary · context
    Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat…
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with severe obesity due to a homozygous MC4R mutation, fat percentage was 63.7% after one year of liraglutide.

    In plain wordsIn one boy with a gene-related severe obesity, body fat percentage was slightly lower after a year of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFat percentage, case 1 (MC4R mutation)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Fat percentage
    63.7%
    after 1 year

    Source sentences

    Summary
    One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement.
    1 context sentence
    Summary · context
    Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat…
  3. 03HumanCase report or seriesEfficacy outcome

    In a boy with severe obesity due to a homozygous MC4R mutation, the muscle-to-fat ratio z-score was -2.34 after one year of liraglutide.

    In plain wordsIn one boy with a gene-related severe obesity, the muscle-to-fat ratio changed little after a year of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseMuscle-to-fat ratio z-score, case 1 (MC4R mutation)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    MFR z-score
    −2.34 z-score
    after 1 year

    Source sentences

    Summary
    One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement.
    1 context sentence
    Summary · context
    Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat…
  4. 04HumanCase report or seriesEfficacy outcome

    In a boy with severe obesity and NAFLD due to a homozygous MC4R mutation, one year of liraglutide was accompanied by biochemical improvement.

    In plain wordsIn one boy with a gene-related severe obesity and fatty liver, blood tests improved during a year of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBiochemical parameters, case 1 (MC4R mutation)
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement.
    1 context sentence
    Summary · context
    Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat…
  5. 05HumanCase report or seriesEfficacy outcome

    In a boy with obesity, diabetes and NAFLD, liraglutide augmented the improvement in weight status (BMI 68th percentile) beyond lifestyle changes.

    In plain wordsIn one boy with obesity and diabetes, adding liraglutide to lifestyle changes improved weight status further.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI percentile, case 2 (HNF1A and LDLR mutations)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI percentile
    68 percentile
    with liraglutide

    Source sentences

    Summary
    Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases.
    1 context sentence
    Summary · context
    Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases.
  6. 06HumanCase report or seriesEfficacy outcome

    In a boy with obesity, diabetes and NAFLD, fat percentage was 22.6% with liraglutide, down from 32.8% on lifestyle modification alone.

    In plain wordsIn one boy with obesity and diabetes, body fat percentage fell further when liraglutide was added to lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    DecreaseFat percentage, case 2 (HNF1A and LDLR mutations)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Fat percentage
    22.6%
    with liraglutide

    Source sentences

    Summary
    Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases.
    1 context sentence
    Summary · context
    Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases.
  7. 07HumanCase report or seriesEfficacy outcome

    In a boy with obesity, diabetes and NAFLD, the muscle-to-fat ratio z-score improved to -1.13 with liraglutide, from -1.63 on lifestyle modification alone.

    In plain wordsIn one boy with obesity and diabetes, the muscle-to-fat ratio improved further when liraglutide was added to lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    IncreaseMuscle-to-fat ratio z-score, case 2 (HNF1A and LDLR mutations)
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MFR z-score
    −1.13 z-score
    with liraglutide

    Source sentences

    Summary
    Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases.
    1 context sentence
    Summary · context
    Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases.
  8. 08HumanCase report or seriesEfficacy outcome

    In a boy with obesity, diabetes and NAFLD, liraglutide treatment was accompanied by normalization of liver transaminases that lifestyle changes had not achieved.

    In plain wordsIn one boy with obesity and fatty liver, liver enzymes returned to normal after liraglutide was added to lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver transaminases, case 2 (HNF1A and LDLR mutations)
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases.
    1 context sentence
    Summary · context
    Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases.
  9. 09HumanCase report or seriesEfficacy outcome

    In a patient with spinal muscular atrophy type 3 and sarcopenic obesity, liraglutide led to gradual recovery of metabolic complications, allowing other medications to be tapered down.

    In plain wordsIn one young man with spinal muscular atrophy and obesity, liraglutide was followed by gradual recovery of metabolic problems and fewer other drugs.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMetabolic complications, case 3 (spinal muscular atrophy)
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications.
    1 context sentence
    Summary · context
    Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.